



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	2014_JAMPS_14216
Title of the Manuscript:	The efficacy of intravenous immunoglobulin in the treatment of patients with acute disseminated encephalomyelitis
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	This article deals with the treatment of relapsing ADEM, using intravenous immunoglobulins as an add-on treatment of steroids. Treated patients showed less relapses and a better recovery. The subject is interesting but this article needs real improvements. Abstract: Text should be reorganized to focus on results. Details upon methods should be shortened. Text should be reorganized in the introduction. Authors state that increasing the efficacy of treatment in ADEM is a problem. However, ADEM is commonly considered to be associated with a good prognostic. A brief commentary of literature is required. Relapses are not a so common feature of ADEM, and the frequency of relapsing patients upon monophasic patients should be commented. This is one of the key points in differential diagnosis with MS. Diagnostic criteria for ADEM (clinical, radiological and biological) are missing. Demographic and recruitment data are lacking.	



SDI Review Form 1.6

	Lumbar puncture results (intrathecal IgG synthesis, oligoclonal bands?) are not stated, which absolutely required since BOC+ in ADEM are predictive of relapses and of MS diagnosis. How was constructed the control group? Is there any randomisation? is it a prospective / retrospective study? Did relapsing patients receive a second infusion of steroids and/or IVIG? Statistical analysis is not detailed. Baseline comparisons between treated group and control group are lacking (table 1 is far less than sufficient). Stratification of improvement is questionable. An overall score for each group (treated and control) should be preferred. Figures 1, 2 and 3 are redundant with tables. Figure 5: labelled T2 but showing T1 sequences, with different slice levels than figure 4. An extensive english edition is required.	
<u>Minor</u> REVISION comments	Abstract: line 12: "in the treatment of patients with multiphase ADEM"?	
<u>Optional/General</u> comments		

Reviewer Details:

Name:	Anonymous
Department, University & Country	France